Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

COVID-19

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 321 articles: HTML format

Single Articles

October 2025
1. CAI M, Xie Y, Al-Aly Z
   Association of 2024-2025 Covid-19 Vaccine with Covid-19 Outcomes in U.S. Veterans.
   N Engl J Med. 2025 Oct 8. doi: 10.1056/NEJMoa2510226.
   PubMed     Abstract available
   
   
   July 2025
2. PRASAD V, Makary MA
   An Evidence-Based Approach to Covid-19 Vaccination. Reply.
   N Engl J Med. 2025 Jul 9:10.1056/NEJMc2507760#sa6. doi: 10.1056/NEJMc2507760.
   PubMed    
   
   
   
3. MEYEROWITZ EA
   An Evidence-Based Approach to Covid-19 Vaccination.
   N Engl J Med. 2025 Jul 9:10.1056/NEJMc2507760#sa5. doi: 10.1056/NEJMc2507760.
   PubMed    
   
   
   
4. DREKONJA D
   An Evidence-Based Approach to Covid-19 Vaccination.
   N Engl J Med. 2025 Jul 9:10.1056/NEJMc2507760#sa4. doi: 10.1056/NEJMc2507760.
   PubMed    
   
   
   
5. VOHRA-MILLER S, Marnik EA
   An Evidence-Based Approach to Covid-19 Vaccination.
   N Engl J Med. 2025 Jul 9:10.1056/NEJMc2507760#sa3. doi: 10.1056/NEJMc2507760.
   PubMed    
   
   
   
6. HAIDAR G, Hauschildt KE, Michaels MG
   An Evidence-Based Approach to Covid-19 Vaccination.
   N Engl J Med. 2025 Jul 9:10.1056/NEJMc2507760#sa2. doi: 10.1056/NEJMc2507760.
   PubMed    
   
   
   
7. PAPPAS G
   An Evidence-Based Approach to Covid-19 Vaccination.
   N Engl J Med. 2025 Jul 9:10.1056/NEJMc2507760#sa1. doi: 10.1056/NEJMc2507760.
   PubMed    
   
   
   June 2025
8. SCHWARTZ JL
   Revised Recommendations for Covid-19 Vaccines - U.S. Vaccination Policy under Threat.
   N Engl J Med. 2025 Jun 18. doi: 10.1056/NEJMp2507766.
   PubMed    
   
   
   
9. MCINTYRE L, Fergusson D, McArdle T, English S, et al
   A Crossover Trial of Hospital-Wide Lactated Ringer's Solution versus Normal Saline.
   N Engl J Med. 2025 Jun 12. doi: 10.1056/NEJMoa2416761.
   PubMed     Abstract available
   
   
   May 2025
10. PRASAD V, Makary MA
    An Evidence-Based Approach to Covid-19 Vaccination.
    N Engl J Med. 2025 May 20. doi: 10.1056/NEJMsb2506929.
    PubMed    
    
    
    February 2025
11. BROWN JR, Seymour JF, Jurczak W, Aw A, et al
    Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
    N Engl J Med. 2025;392:748-762.
    PubMed     Abstract available
    
    
    
12. WANG JJ, Warkentin TE, Schonborn L, Wheeler MB, et al
    VITT-like Monoclonal Gammopathy of Thrombotic Significance.
    N Engl J Med. 2025 Feb 12. doi: 10.1056/NEJMoa2415930.
    PubMed     Abstract available
    
    
    
13. FURIE RA, Rovin BH, Garg JP, Santiago MB, et al
    Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis.
    N Engl J Med. 2025 Feb 7. doi: 10.1056/NEJMoa2410965.
    PubMed     Abstract available
    
    
    November 2024
14. WANG Q, Guo Y, Ho J, Ho DD, et al
    Activity of Research-Grade Pemivibart against Recent SARS-CoV-2 JN.1 Sublineages.
    N Engl J Med. 2024;391:1863-1864.
    PubMed    
    
    
    
15. SCHMIDT P, Li Y, Popejoy M
    Immunobridging for Pemivibart, a Monoclonal Antibody for Prevention of Covid-19.
    N Engl J Med. 2024;391:1860-1862.
    PubMed    
    
    
    
16. JASTREBOFF AM, le Roux CW, Stefanski A, Aronne LJ, et al
    Tirzepatide for Obesity Treatment and Diabetes Prevention.
    N Engl J Med. 2024 Nov 13. doi: 10.1056/NEJMoa2410819.
    PubMed     Abstract available
    
    
    October 2024
17. XIE Y, Al-Aly Z
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras. Reply.
    N Engl J Med. 2024;391:1659-1660.
    PubMed    
    
    
    
18. YANG C, Tebbutt SJ
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1659.
    PubMed    
    
    
    
19. LITWINSKA-KMIECIK A, Mrowczynski K
    Postacute Sequelae of SARS-CoV-2 Infection in Several Eras.
    N Engl J Med. 2024;391:1658-1659.
    PubMed    
    
    
    
20. BLENDON RJ, Blumenthal D, Glied S, Sommers BD, et al
    Critical Health Care Challenges for the Next U.S. President.
    N Engl J Med. 2024;391:e36.
    PubMed    
    
    
    September 2024
21. 
    What Exactly Is Long Covid?: ITT Episode 37.
    N Engl J Med. 2024;391:e17.
    PubMed    
    
    
    
22. ASHINA M, Phul R, Khodaie M, Lof E, et al
    A Monoclonal Antibody to PACAP for Migraine Prevention.
    N Engl J Med. 2024;391:800-809.
    PubMed     Abstract available
    
    
    
23. ROTTER LK
    "Do You Feel Safe at Home?".
    N Engl J Med. 2024;391:785-787.
    PubMed    
    
    
    August 2024
24. MAITLAND K, Walker AS
    Why Was the Azithromycin "for Life" Trial Necessary?
    N Engl J Med. 2024;391:760-762.
    PubMed    
    
    
    
25. DAVIS E, Mayer S, Pacilli M
    Academic Medical Center-Public Health Partnerships for Outbreak Response - Collaborating with Underresourced Communities.
    N Engl J Med. 2024;391:679-681.
    PubMed    
    
    
    
26. HAYES C
    In Pursuit of Polka Dots.
    N Engl J Med. 2024;391:582-583.
    PubMed    
    
    
    
27. CANDRIAN C, Weissman JS, Tjia J
    SOGI Data Collection - Proceeding, but with Caution.
    N Engl J Med. 2024;391:580-581.
    PubMed    
    
    
    
28. HALABI S, O'Hara GL
    Preparing for the Next Pandemic - Expanding and Coordinating Global Regulatory Capacity.
    N Engl J Med. 2024;391:484-487.
    PubMed    
    
    
    
29. MAKARI GJ, Friedman RA
    Collective Trauma and Commemoration - A Moment of Silence, Please.
    N Engl J Med. 2024;391:487-489.
    PubMed    
    
    
    
30. MIN J
    Studies of Exagamglogene Autotemcel - Age and Place.
    N Engl J Med. 2024;391:571-572.
    PubMed    
    
    
    
31. HAMMOND J, Fountaine RJ, Bao W
    Nirmatrelvir for Adult Outpatients with Covid-19. Reply.
    N Engl J Med. 2024;391:478-479.
    PubMed    
    
    
    
32. SHANG L, Wang Y, Cao B
    Nirmatrelvir for Adult Outpatients with Covid-19.
    N Engl J Med. 2024;391:477-478.
    PubMed    
    
    
    
33. BLAIS JE
    Nirmatrelvir for Adult Outpatients with Covid-19.
    N Engl J Med. 2024;391:477.
    PubMed    
    
    
    
34. SHAN D, Zhang G, Du Z
    Nirmatrelvir for Adult Outpatients with Covid-19.
    N Engl J Med. 2024;391:477.
    PubMed    
    
    
    July 2024
35. SINHA MS, Parmet WE, Gonsalves GS
    Deja Vu All Over Again - Refusing to Learn the Lessons of Covid-19.
    N Engl J Med. 2024 Jul 24. doi: 10.1056/NEJMp2406427.
    PubMed    
    
    
    
36. HAMMOND J, Yunis C, Fountaine RJ, Luscan G, et al
    Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
    N Engl J Med. 2024;391:224-234.
    PubMed     Abstract available
    
    
    
37. MEISSNER HC, Kapogiannis BG, Wolfe DN
    Anticipating the Next Pandemic.
    N Engl J Med. 2024;391:196-199.
    PubMed    
    
    
    
38. XIE Y, Choi T, Al-Aly Z
    Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras.
    N Engl J Med. 2024 Jul 17. doi: 10.1056/NEJMoa2403211.
    PubMed     Abstract available
    
    
    
39. ROSEN CJ
    Viral Variants, Vaccinations, and Long Covid - New Insights.
    N Engl J Med. 2024 Jul 17. doi: 10.1056/NEJMe2407575.
    PubMed    
    
    
    
40. SALMON DA, Orenstein WA, Plotkin SA, Chen RT, et al
    Funding Postauthorization Vaccine-Safety Science.
    N Engl J Med. 2024;391:102-105.
    PubMed    
    
    
    June 2024
41. CHEHADE M, Dellon ES, Spergel JM, Collins MH, et al
    Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
    N Engl J Med. 2024;390:2239-2251.
    PubMed     Abstract available
    
    
    
42. SAMET JH, El-Bassel N, Winhusen TJ, Jackson RD, et al
    Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths.
    N Engl J Med. 2024 Jun 16. doi: 10.1056/NEJMoa2401177.
    PubMed     Abstract available
    
    
    
43. OWUSU-ANSAH S, Green Rodgers P
    Reviving Hearts - Uniting Communities with Lifesaving Bystander CPR.
    N Engl J Med. 2024;390:2040-2041.
    PubMed    
    
    
    
44. HAMPSHIRE A, Elliott P
    Cognition and Memory after Covid-19 in a Large Community Sample. Reply.
    N Engl J Med. 2024;390:2035.
    PubMed    
    
    
    
45. XU L, Huang X, Li Y
    Cognition and Memory after Covid-19 in a Large Community Sample.
    N Engl J Med. 2024;390:2034-2035.
    PubMed    
    
    
    
46. BUONSENSO D
    Cognition and Memory after Covid-19 in a Large Community Sample.
    N Engl J Med. 2024;390:2034.
    PubMed    
    
    
    May 2024
47. HALABI S, Gostin LO, Egbokhare O, Kavanagh MM, et al
    Global Health Law for a Safer and Fairer World.
    N Engl J Med. 2024;390:1925-1931.
    PubMed    
    
    
    
48. LIN DY, Du Y, Xu Y, Paritala S, et al
    Durability of XBB.1.5 Vaccines against Omicron Subvariants.
    N Engl J Med. 2024 May 29. doi: 10.1056/NEJMc2402779.
    PubMed    
    
    
    
49. HERBERT C, McManus DD, Soni A
    False Positive Covid-19 Rapid Antigen Tests. Reply.
    N Engl J Med. 2024;390:1836.
    PubMed    
    
    
    
50. YANG C, Espin E, Tebbutt SJ
    False Positive Covid-19 Rapid Antigen Tests.
    N Engl J Med. 2024;390:1835-1836.
    PubMed    
    
    
    
51. SCHUBACH A, Ricotta D, Kittleson MM
    To Preround or Not to Preround.
    N Engl J Med. 2024;390:1824-1826.
    PubMed    
    
    
    
52. WANG JJ, Schonborn L, Warkentin TE, Chataway T, et al
    Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.
    N Engl J Med. 2024;390:1827-1829.
    PubMed    
    
    
    April 2024
53. WANG Y, Hu H, Cao B
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19. Reply.
    N Engl J Med. 2024;390:1534-1535.
    PubMed    
    
    
    
54. SELVI-SABATER P, de la Rubia Orti JE, Urbieta-Sanz E
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    N Engl J Med. 2024;390:1534.
    PubMed    
    
    
    
55. MOSER CB, Li JZ, Hughes MD
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    N Engl J Med. 2024;390:1533-1534.
    PubMed    
    
    
    
56. GANDHI RT, Hirsch M
    Treating Acute Covid-19 - Final Chapters Still Unwritten.
    N Engl J Med. 2024;390:1234-1236.
    PubMed    
    
    
    
57. HAMMOND J, Fountaine RJ, Yunis C, Fleishaker D, et al
    Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19.
    N Engl J Med. 2024;390:1186-1195.
    PubMed     Abstract available
    
    
    February 2024
58. ELLINGJORD-DALE M, Brunvoll SH, Soraas A
    Prospective Memory Assessment before and after Covid-19.
    N Engl J Med. 2024;390:863-865.
    PubMed    
    
    
    
59. AL-ALY Z, Rosen CJ
    Long Covid and Impaired Cognition - More Evidence and More Work to Do.
    N Engl J Med. 2024;390:858-860.
    PubMed    
    
    
    
60. HAMPSHIRE A, Azor A, Atchison C, Trender W, et al
    Cognition and Memory after Covid-19 in a Large Community Sample.
    N Engl J Med. 2024;390:806-818.
    PubMed     Abstract available
    
    
    
61. 
    Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines.
    N Engl J Med. 2024;390:772.
    PubMed    
    
    
    
62. BENEZECH S, Khoryati L, Belot A
    More on Pre-Covid-19, SARS-CoV-2-Negative MIS-C. Reply.
    N Engl J Med. 2024;390:771-772.
    PubMed    
    
    
    
63. FRANCO A, Tremoulet A, Burns JC
    More on Pre-Covid-19, SARS-CoV-2-Negative MIS-C.
    N Engl J Med. 2024;390:771.
    PubMed    
    
    
    
64. HERBERT C, McManus DD, Soni A
    Persistent False Positive Covid-19 Rapid Antigen Tests.
    N Engl J Med. 2024;390:764-765.
    PubMed    
    
    
    
65. VERMERSCH P, Granziera C, Mao-Draayer Y, Cutter G, et al
    Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
    N Engl J Med. 2024;390:589-600.
    PubMed     Abstract available
    
    
    
66. BISSONNETTE R, Pinter A, Ferris LK, Gerdes S, et al
    An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
    N Engl J Med. 2024;390:510-521.
    PubMed     Abstract available
    
    
    January 2024
67. MISSET B, Desmecht D, Laterre PF
    Convalescent Plasma for Covid-19-Induced ARDS. Reply.
    N Engl J Med. 2024;390:386.
    PubMed    
    
    
    
68. CASADEVALL A, Shoham S, Pirofski LA
    Convalescent Plasma for Covid-19-Induced ARDS.
    N Engl J Med. 2024;390:385-386.
    PubMed    
    
    
    
69. SENEFELD JW, Henderson JP, Joyner MJ
    Convalescent Plasma for Covid-19-Induced ARDS.
    N Engl J Med. 2024;390:385.
    PubMed    
    
    
    
70. BORGHESI A, Casanova JL
    Convalescent Plasma for Covid-19-Induced ARDS.
    N Engl J Med. 2024;390:384-385.
    PubMed    
    
    
    
71. CAO B, Wang Y, Lu H, Huang C, et al
    Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19.
    N Engl J Med. 2024;390:230-241.
    PubMed     Abstract available
    
    
    December 2023
72. 
    Covid Update: ITT Episode 23.
    N Engl J Med. 2023;389:e52.
    PubMed    
    
    
    November 2023
73. BENEZECH S, Khoryati L, Cognard J, Netea SA, et al
    Pre-Covid-19, SARS-CoV-2-Negative Multisystem Inflammatory Syndrome in Children.
    N Engl J Med. 2023;389:2105-2107.
    PubMed    
    
    
    
74. WANG Y, Guo Z, Ye B, Liu L, et al
    Association of SARS-CoV-2 Infection during Early Weeks of Gestation with Situs Inversus.
    N Engl J Med. 2023;389:1722-1724.
    PubMed    
    
    
    October 2023
75. MISSET B, Piagnerelli M, Hoste E, Dardenne N, et al
    Convalescent Plasma for Covid-19-Induced ARDS in Mechanically Ventilated Patients.
    N Engl J Med. 2023;389:1590-1600.
    PubMed     Abstract available
    
    
    
76. BLADH O, Greilert-Norin N, Havervall S, Marking U, et al
    Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.
    N Engl J Med. 2023;389:1626-1628.
    PubMed    
    
    
    
77. HILLS TE, Lorenzi E, Berry LR, Shyamsundar M, et al
    Simvastatin in Critically Ill Patients with Covid-19.
    N Engl J Med. 2023 Oct 25. doi: 10.1056/NEJMoa2309995.
    PubMed     Abstract available
    
    
    
78. 
    The Long Haul of Long Covid.
    N Engl J Med. 2023;389:e29.
    PubMed    
    
    
    
79. ABI-RACHED JM, Brandt AM
    Do Pandemics Ever End?
    N Engl J Med. 2023;389:1349-1351.
    PubMed    
    
    
    September 2023
80. BOULWARE DR, Lindsell CJ, Stewart TG, Hernandez AF, et al
    Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.
    N Engl J Med. 2023;389:1085-1095.
    PubMed     Abstract available
    
    
    August 2023
81. MURRAY EJ, Cowger TL, Hall KT
    Lifting Universal School Masking - Covid-19 Incidence among Students and Staff. Reply.
    N Engl J Med. 2023;389:580.
    PubMed    
    
    
    
82. MARINE JE
    Lifting Universal School Masking - Covid-19 Incidence among Students and Staff.
    N Engl J Med. 2023;389:579.
    PubMed    
    
    
    
83. LADHANI SN, Andrews N, Ramsay ME
    Lifting Universal School Masking - Covid-19 Incidence among Students and Staff.
    N Engl J Med. 2023;389:579.
    PubMed    
    
    
    
84. RUSSELL FM, Curtis N, Carlin J
    Lifting Universal School Masking - Covid-19 Incidence among Students and Staff.
    N Engl J Med. 2023;389:578-579.
    PubMed    
    
    
    
85. KRISCHER JP, Lernmark A, Hagopian WA, Rewers MJ, et al
    SARS-CoV-2 - No Increased Islet Autoimmunity or Type 1 Diabetes in Teens.
    N Engl J Med. 2023;389:474-475.
    PubMed    
    
    
    July 2023
86. BECERRA X, Jha A
    Project NextGen - Defeating SARS-CoV-2 and Preparing for the Next Pandemic.
    N Engl J Med. 2023 Jul 26. doi: 10.1056/NEJMp2307867.
    PubMed    
    
    
    
87. ARBEL R, Sergienko R, Netzer D, Hammerman A, et al
    Potential "Healthy Vaccinee Bias" in a Study of BNT162b2 Vaccine against Covid-19. Reply.
    N Engl J Med. 2023;389:285-286.
    PubMed    
    
    
    
88. HOEG TB, Duriseti R, Prasad V
    Potential "Healthy Vaccinee Bias" in a Study of BNT162b2 Vaccine against Covid-19.
    N Engl J Med. 2023;389:284-285.
    PubMed    
    
    
    
89. MCCRINDLE BW, Manlhiot C
    More on SARS-CoV-2 Variants and Pediatric Multisystem Inflammatory Syndrome. Reply.
    N Engl J Med. 2023;389:287-288.
    PubMed    
    
    
    
90. XIA CY, Niu MM, Hu P
    More on SARS-CoV-2 Variants and Pediatric Multisystem Inflammatory Syndrome.
    N Engl J Med. 2023;389:287.
    PubMed    
    
    
    
91. PITTET LF, Messina NL, Curtis N
    BCG to Protect against Covid-19 in Health Care Workers. Reply.
    N Engl J Med. 2023;389:192.
    PubMed    
    
    
    
92. BENN CS, Netea MG, Aaby P
    BCG to Protect against Covid-19 in Health Care Workers.
    N Engl J Med. 2023;389:191-192.
    PubMed    
    
    
    
93. LOPEZ-CAMPOS GH, Valvano MA
    BCG to Protect against Covid-19 in Health Care Workers.
    N Engl J Med. 2023;389:191.
    PubMed    
    
    
    June 2023
94. CAO Z, Gao Y, Zhao R
    VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. Reply.
    N Engl J Med. 2023;388:2396-2397.
    PubMed    
    
    
    
95. LI Y
    VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    N Engl J Med. 2023;388:2396.
    PubMed    
    
    
    
96. EDWARDS JL
    VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    N Engl J Med. 2023;388:2395-2396.
    PubMed    
    
    
    
97. BERGMANN F, Jorda A, Zeitlinger M
    VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    N Engl J Med. 2023;388:2395.
    PubMed    
    
    
    
98. LIN DY, Fleming TR
    VV116 or Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
    N Engl J Med. 2023;388:2395.
    PubMed    
    
    
    
99. MCGARRY BE, Gandhi AD, Barnett ML
    Covid-19 Surveillance Testing in Nursing Homes. Reply.
    N Engl J Med. 2023;388:2207-2208.
    PubMed    
    
    
    
100. STALL NM, Kain DC, Johnstone J
     Covid-19 Surveillance Testing in Nursing Homes.
     N Engl J Med. 2023;388:2207.
     PubMed    
     
     
     
101. DORFMAN D, Berger Z
     Approving Workplace Accommodations for Patients with Long Covid - Advice for Clinicians.
     N Engl J Med. 2023;388:2115-2117.
     PubMed    
     
     
     
102. NIKOLICH JZ, Rosen CJ
     Toward Comprehensive Care for Long Covid.
     N Engl J Med. 2023;388:2113-2115.
     PubMed    
     
     
     
103. GOSTIN LO, Gronvall GK
     The Origins of Covid-19 - Why It Matters (and Why It Doesn't).
     N Engl J Med. 2023 Jun 7. doi: 10.1056/NEJMp2305081.
     PubMed    
     
     
     
104. TSUBOI M, Herbst RS, John T, Kato T, et al
     Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
     N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304594.
     PubMed     Abstract available
     
     
     
105. REIS G, Mills EJ, Glenn JS
     Pegylated Interferon Lambda for Covid-19. Reply.
     N Engl J Med. 2023;388:2108.
     PubMed    
     
     
     
106. WANG M, Tang L, Huang L
     Pegylated Interferon Lambda for Covid-19.
     N Engl J Med. 2023;388:2107-2108.
     PubMed    
     
     
     
107. ANDREAKOS E, Tsiodras S
     Pegylated Interferon Lambda for Covid-19.
     N Engl J Med. 2023;388:2107.
     PubMed    
     
     
     May 2023
108. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: The Lasting Effects of Covid-19.
     N Engl J Med. 2023;388:e76.
     PubMed    
     
     
     
109. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Ending the Covid-19 Emergency.
     N Engl J Med. 2023;388:e72.
     PubMed    
     
     
     
110. LISCO A, Ortega-Villa AM, Mystakelis H, Anderson MV, et al
     Reappraisal of Idiopathic CD4 Lymphocytopenia at 30 Years.
     N Engl J Med. 2023;388:1680-1691.
     PubMed     Abstract available
     
     
     April 2023
111. PITTET LF, Messina NL, Orsini F, Moore CL, et al
     Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers.
     N Engl J Med. 2023;388:1582-1596.
     PubMed     Abstract available
     
     
     
112. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: When to Get a Second Covid-19 Booster Shot.
     N Engl J Med. 2023;388:e64.
     PubMed    
     
     
     March 2023
113. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Ending the Covid-19 Public Health Emergency.
     N Engl J Med. 2023;388:e53.
     PubMed    
     
     
     
114. JABAGI MJ, Bertrand M, Botton J, Le Vu S, et al
     Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster.
     N Engl J Med. 2023 Mar 29. doi: 10.1056/NEJMc2302134.
     PubMed    
     
     
     
115. MCGARRY BE, Gandhi AD, Barnett ML
     Covid-19 Surveillance Testing and Resident Outcomes in Nursing Homes.
     N Engl J Med. 2023;388:1101-1110.
     PubMed     Abstract available
     
     
     
116. MCCRINDLE BW, Harahsheh AS, Handoko R, Raghuveer G, et al
     SARS-CoV-2 Variants and Multisystem Inflammatory Syndrome in Children.
     N Engl J Med. 2023 Mar 22. doi: 10.1056/NEJMc2215074.
     PubMed    
     
     
     
117. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: The Future of Covid-19 Research.
     N Engl J Med. 2023;388:e39.
     PubMed    
     
     
     
118. MANSOUR MK, King JD, Chen ST, Fishman JA, et al
     Case 7-2023: A 70-Year-Old Man with Covid-19, Respiratory Failure, and Rashes.
     N Engl J Med. 2023;388:926-937.
     PubMed    
     
     
     
119. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: The Path Forward for Covid-19 Therapeutics.
     N Engl J Med. 2023;388:e36.
     PubMed    
     
     
     
120. ALVES K, Plested JS, Galbiati S, Chau G, et al
     Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
     N Engl J Med. 2023;388:857-859.
     PubMed    
     
     
     
121. OFFIT PA
     Bivalent Covid-19 Vaccines. Reply.
     N Engl J Med. 2023;388:10.
     PubMed    
     
     
     
122. MARKS PW, Califf RM
     Bivalent Covid-19 Vaccines.
     N Engl J Med. 2023;388:10.
     PubMed    
     
     
     
123. LI D, Duan M, Wang X, Gao P, et al
     Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines.
     N Engl J Med. 2023 Mar 1. doi: 10.1056/NEJMc2216233.
     PubMed    
     
     
     February 2023
124. 
     Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.
     N Engl J Med. 2023;388:672.
     PubMed    
     
     
     
125. RUBIN EJ, Baden LR, Graham BS, Morrissey S, et al
     Audio Interview: What to Expect from Covid-19 Vaccines.
     N Engl J Med. 2023;388:e23.
     PubMed    
     
     
     
126. MUNOZ FM, Sher LD, Sabharwal C, Gurtman A, et al
     Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.
     N Engl J Med. 2023;388:621-634.
     PubMed     Abstract available
     
     
     
127. CHEMAITELLY H, Tang P, Coyle P, Yassine HM, et al
     Protection against Reinfection with the Omicron BA.2.75 Subvariant.
     N Engl J Med. 2023;388:665-667.
     PubMed    
     
     
     
128. HUTH L, Schafer L, Almanzar G, Lupoli G, et al
     Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis.
     N Engl J Med. 2023 Feb 15. doi: 10.1056/NEJMc2216309.
     PubMed    
     
     
     
129. WITBERG G
     More on Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. Reply.
     N Engl J Med. 2023;388:576.
     PubMed    
     
     
     
130. TOVANI-PALONE MR, Patil S
     More on Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
     N Engl J Med. 2023;388:576.
     PubMed    
     
     
     
131. REIS G, Moreira Silva EAS, Medeiros Silva DC, Thabane L, et al
     Early Treatment with Pegylated Interferon Lambda for Covid-19.
     N Engl J Med. 2023;388:518-528.
     PubMed     Abstract available
     
     
     
132. WANG Q, Bowen A, Valdez R, Gherasim C, et al
     Antibody Response to Omicron BA.4-BA.5 Bivalent Booster.
     N Engl J Med. 2023;388:567-569.
     PubMed    
     
     
     
133. EL-SADR WM, Vasan A, El-Mohandes A
     Facing the New Covid-19 Reality.
     N Engl J Med. 2023;388:385-387.
     PubMed    
     
     
     
134. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Updating and Standardizing Covid-19 Vaccines.
     N Engl J Med. 2023;388:e21.
     PubMed    
     
     
     January 2023
135. 
     Covid Vaccines - Playing the Long Game.
     N Engl J Med. 2023;388:e5.
     PubMed    
     
     
     
136. ZOU J, Kurhade C, Patel S, Kitchin N, et al
     Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine.
     N Engl J Med. 2023 Jan 25. doi: 10.1056/NEJMc2214916.
     PubMed    
     
     
     
137. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Weighing the Protective Value of Covid-19 Infection.
     N Engl J Med. 2023;388:e13.
     PubMed    
     
     
     
138. WINOKUR P, Gayed J, Fitz-Patrick D, Thomas SJ, et al
     Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years.
     N Engl J Med. 2023;388:214-227.
     PubMed     Abstract available
     
     
     
139. MILLER J, Hachmann NP, Collier AY, Lasrado N, et al
     Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1.
     N Engl J Med. 2023 Jan 18. doi: 10.1056/NEJMc2214314.
     PubMed    
     
     
     
140. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Covid-19 Vaccines and New Viral Variants.
     N Engl J Med. 2023;388:e8.
     PubMed    
     
     
     
141. OFFIT PA
     Bivalent Covid-19 Vaccines - A Cautionary Tale.
     N Engl J Med. 2023 Jan 11. doi: 10.1056/NEJMp2215780.
     PubMed    
     
     
     
142. COLLIER AY, Miller J, Hachmann NP, McMahan K, et al
     Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters.
     N Engl J Med. 2023 Jan 11. doi: 10.1056/NEJMc2213948.
     PubMed    
     
     
     
143. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: The Expanding Arsenal of Oral Agents to Treat Covid-19.
     N Engl J Med. 2023;388:e7.
     PubMed    
     
     
     
144. IMAI M, Ito M, Kiso M, Yamayoshi S, et al
     Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB.
     N Engl J Med. 2023;388:89-91.
     PubMed    
     
     
     December 2022
145. ARBEL R, Wolff Sagy Y, Hammerman A
     Nirmatrelvir Use during the Omicron Surge. Reply.
     N Engl J Med. 2022;387:2480-2481.
     PubMed    
     
     
     
146. WEISS G
     Nirmatrelvir Use during the Omicron Surge.
     N Engl J Med. 2022;387:2480.
     PubMed    
     
     
     
147. NIELD B
     Nirmatrelvir Use during the Omicron Surge.
     N Engl J Med. 2022;387:2479-2480.
     PubMed    
     
     
     
148. SWETS MC, de Boer MGJ, Groeneveld GH
     Nirmatrelvir Use during the Omicron Surge.
     N Engl J Med. 2022;387:2479.
     PubMed    
     
     
     
149. CAO Z, Gao W, Bao H, Feng H, et al
     VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.
     N Engl J Med. 2022 Dec 28. doi: 10.1056/NEJMoa2208822.
     PubMed     Abstract available
     
     
     
150. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Potential Covid Vaccine Strategies.
     N Engl J Med. 2022;387:e75.
     PubMed    
     
     
     
151. REIS G, Mills EJ
     Ivermectin Treatment for Covid-19. Reply.
     N Engl J Med. 2022;387:e66.
     PubMed    
     
     
     
152. BARUS R, Gautier S, Wabont G
     Ivermectin Treatment for Covid-19.
     N Engl J Med. 2022;387:e66.
     PubMed    
     
     
     
153. MEJIA JH, Jimenez CA
     Ivermectin Treatment for Covid-19.
     N Engl J Med. 2022;387:e66.
     PubMed    
     
     
     
154. FURLAN L
     Ivermectin Treatment for Covid-19.
     N Engl J Med. 2022;387:e66.
     PubMed    
     
     
     
155. BRAMANTE CT, Buse JB, Boulware DR
     Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19. Reply.
     N Engl J Med. 2022;387:e65.
     PubMed    
     
     
     
156. SHUKLA AK, Misra S
     Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
     N Engl J Med. 2022;387:e65.
     PubMed    
     
     
     
157. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Applying New Studies of Mpox and Ebola to Covid-19.
     N Engl J Med. 2022;387:e74.
     PubMed    
     
     
     
158. GILBERT PB, Donis RO, Koup RA, Fong Y, et al
     A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines.
     N Engl J Med. 2022;387:2203-2206.
     PubMed    
     
     
     
159. RUBIN EJ, Baden LR, Hlatshwayo Davis M, Morrissey S, et al
     Audio Interview: Covid-19 and Health Equity.
     N Engl J Med. 2022;387:e73.
     PubMed    
     
     
     
160. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Five Disease Outbreaks beyond Covid-19.
     N Engl J Med. 2022;387:e68.
     PubMed    
     
     
     
161. TAKASHITA E, Yamayoshi S, Halfmann P, Wilson N, et al
     In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6.
     N Engl J Med. 2022;387:2094-2097.
     PubMed    
     
     
     November 2022
162. ABERG M, Smed-Sorensen A, Thalin C
     Mucosal IgA against SARS-CoV-2 Omicron Infection. Reply.
     N Engl J Med. 2022;387:e55.
     PubMed    
     
     
     
163. ZUO F, Marcotte H, Hammarstrom L, Pan-Hammarstrom Q, et al
     Mucosal IgA against SARS-CoV-2 Omicron Infection.
     N Engl J Med. 2022;387:e55.
     PubMed    
     
     
     
164. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Making Choices about Covid-19.
     N Engl J Med. 2022;387:e64.
     PubMed    
     
     
     
165. RUBIN EJ, Baden LR, Marks P, Morrissey S, et al
     Audio Interview: The FDA and Covid-19 Vaccines.
     N Engl J Med. 2022;387:e60.
     PubMed    
     
     
     
166. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Masking and Covid-19.
     N Engl J Med. 2022;387:e56.
     PubMed    
     
     
     
167. VENKATARAMANI V, Winkler F
     Cognitive Deficits in Long Covid-19.
     N Engl J Med. 2022;387:1813-1815.
     PubMed    
     
     
     
168. FRICCHIONE GL, Paul AB, Chemali Z, Kritzer MD, et al
     Case 34-2022: A 57-Year-Old Woman with Covid-19 and Delusions.
     N Engl J Med. 2022;387:1795-1803.
     PubMed    
     
     
     
169. RAIFMAN J, Green T
     Universal Masking Policies in Schools and Mitigating the Inequitable Costs of Covid-19.
     N Engl J Med. 2022 Nov 9. doi: 10.1056/NEJMe2213556.
     PubMed    
     
     
     
170. COWGER TL, Murray EJ, Clarke J, Bassett MT, et al
     Lifting Universal Masking in Schools - Covid-19 Incidence among Students and Staff.
     N Engl J Med. 2022 Nov 9. doi: 10.1056/NEJMoa2211029.
     PubMed     Abstract available
     
     
     
171. CANETTI M, Barda N, Gilboa M, Indenbaum V, et al
     Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose.
     N Engl J Med. 2022 Nov 9. doi: 10.1056/NEJMc2211283.
     PubMed    
     
     
     
172. CHESKES S, Verbeek PR, Drennan IR, McLeod SL, et al
     Defibrillation Strategies for Refractory Ventricular Fibrillation.
     N Engl J Med. 2022 Nov 6. doi: 10.1056/NEJMoa2207304.
     PubMed     Abstract available
     
     
     
173. RUBIN EJ, Baden LR, Hardin CC, Morrissey S, et al
     Audio Interview: Caring for Hospitalized Patients with Covid-19.
     N Engl J Med. 2022;387:e51.
     PubMed    
     
     
     
174. CHEMAITELLY H, AlMukdad S, Ayoub HH, Altarawneh HN, et al
     Covid-19 Vaccine Protection among Children and Adolescents in Qatar.
     N Engl J Med. 2022 Nov 2. doi: 10.1056/NEJMoa2210058.
     PubMed     Abstract available
     
     
     October 2022
175. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Assessing the Effect of Vaccination and Prior SARS-CoV-2 Infection.
     N Engl J Med. 2022;387:e50.
     PubMed    
     
     
     
176. EMANUEL EJ, Upshur REG, Smith MJ
     What Covid Has Taught the World about Ethics.
     N Engl J Med. 2022;387:1542-1545.
     PubMed    
     
     
     
177. CHIN ET, Leidner D, Lamson L, Lucas K, et al
     Protection against Omicron from Vaccination and Previous Infection in a Prison System.
     N Engl J Med. 2022 Oct 26. doi: 10.1056/NEJMoa2207082.
     PubMed     Abstract available
     
     
     
178. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Covid-19: Where Are We Heading?
     N Engl J Med. 2022;387:e47.
     PubMed    
     
     
     
179. ANDERSON EJ, Creech CB, Berthaud V, Piramzadian A, et al
     Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
     N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMoa2209367.
     PubMed     Abstract available
     
     
     
180. HACHMANN NP, Miller J, Collier AY, Barouch DH, et al
     Neutralization Escape by SARS-CoV-2 Omicron Subvariant BA.4.6.
     N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMc2212117.
     PubMed    
     
     
     
181. WITBERG G, Magen O, Hoss S, Talmor-Barkan Y, et al
     Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
     N Engl J Med. 2022 Oct 19. doi: 10.1056/NEJMc2207270.
     PubMed    
     
     
     
182. RUBIN EJ, Baden LR, Neuzil KM, Morrissey S, et al
     Audio Interview: Developing New Covid-19 Vaccines.
     N Engl J Med. 2022;387:e44.
     PubMed    
     
     
     
183. CHEMAITELLY H, Ayoub HH, Tang P, Hasan MR, et al
     Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2.
     N Engl J Med. 2022 Oct 12. doi: 10.1056/NEJMc2211055.
     PubMed    
     
     
     
184. ALTARAWNEH HN, Chemaitelly H, Ayoub HH, Hasan MR, et al
     Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants.
     N Engl J Med. 2022 Oct 5. doi: 10.1056/NEJMc2209306.
     PubMed    
     
     
     September 2022
185. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Assessing Bivalent Vaccines against Covid-19.
     N Engl J Med. 2022;387:e37.
     PubMed    
     
     
     
186. TAKASHITA E, Yamayoshi S, Fukushi S, Suzuki T, et al
     Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75.
     N Engl J Med. 2022;387:1236-1238.
     PubMed    
     
     
     
187. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Can Vaccines Prevent Transmission of Covid-19?
     N Engl J Med. 2022;387:e30.
     PubMed    
     
     
     
188. THURNER L, Kessel C, Fadle N, Regitz E, et al
     IL-1RA Antibodies in Myocarditis after SARS-CoV-2 Vaccination.
     N Engl J Med. 2022 Sep 21. doi: 10.1056/NEJMc2205667.
     PubMed    
     
     
     
189. CHALKIAS S, Harper C, Vrbicky K, Walsh SR, et al
     A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
     N Engl J Med. 2022 Sep 16. doi: 10.1056/NEJMoa2208343.
     PubMed     Abstract available
     
     
     
190. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Developing Mucosal Immunity to Covid-19.
     N Engl J Med. 2022;387:e29.
     PubMed    
     
     
     
191. HAVERVALL S, Marking U, Svensson J, Greilert-Norin N, et al
     Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.
     N Engl J Med. 2022 Sep 14. doi: 10.1056/NEJMc2209651.
     PubMed    
     
     
     
192. COLLIE S, Nayager J, Bamford L, Bekker LG, et al
     Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.
     N Engl J Med. 2022 Sep 14. doi: 10.1056/NEJMc2210093.
     PubMed    
     
     
     
193. HERRERA-COMOGLIO R, Lane S
     Vaccine-Induced Immune Thrombocytopenia and Thrombosis after the Sputnik V Vaccine.
     N Engl J Med. 2022 Sep 14. doi: 10.1056/NEJMc2210813.
     PubMed    
     
     
     
194. SHEN X, Chalkias S, Feng J, Chen X, et al
     Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination.
     N Engl J Med. 2022 Sep 9. doi: 10.1056/NEJMc2210648.
     PubMed    
     
     
     
195. SULLIVAN DJ, Gebo KA, Hanley DF
     Convalescent Plasma for Covid-19. Reply.
     N Engl J Med. 2022;387:955-956.
     PubMed    
     
     
     
196. PANETH N
     Convalescent Plasma for Covid-19.
     N Engl J Med. 2022;387:955.
     PubMed    
     
     
     
197. JOYNER MJ, Pirofski LA
     Convalescent Plasma for Covid-19.
     N Engl J Med. 2022;387:955.
     PubMed    
     
     
     
198. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Rolling Out New Covid-19 Vaccines.
     N Engl J Med. 2022;387:e26.
     PubMed    
     
     
     
199. CHARNESS ME, Gupta K, Stack G, Strymish J, et al
     Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment.
     N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2206449.
     PubMed    
     
     
     
200. QU P, Faraone JN, Evans JP, Zheng YM, et al
     Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
     N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2210546.
     PubMed    
     
     
     
201. ANDERSON AS, Caubel P, Rusnak JM
     Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19.
     N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2205944.
     PubMed    
     
     
     
202. LIN DY, Gu Y, Xu Y, Zeng D, et al
     Effects of Vaccination and Previous Infection on Omicron Infections in Children.
     N Engl J Med. 2022 Sep 7. doi: 10.1056/NEJMc2209371.
     PubMed    
     
     
     
203. DUPONT SC, Galea S
     Science, Competing Values, and Trade-offs in Public Health - The Example of Covid-19 and Masking.
     N Engl J Med. 2022 Sep 3. doi: 10.1056/NEJMp2207670.
     PubMed    
     
     
     
204. RUBIN EJ, Baden LR, Swaminathan S, Morrissey S, et al
     Audio Interview: Covid-19 and the WHO.
     N Engl J Med. 2022;387:e24.
     PubMed    
     
     
     August 2022
205. BAROUCH DH
     Covid-19 Vaccines - Immunity, Variants, Boosters.
     N Engl J Med. 2022 Aug 31. doi: 10.1056/NEJMra2206573.
     PubMed    
     
     
     
206. MALATO J, Ribeiro RM, Leite PP, Casaca P, et al
     Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants.
     N Engl J Med. 2022 Aug 31. doi: 10.1056/NEJMc2209479.
     PubMed    
     
     
     
207. MACDONALD SM, Berv J
     Losing Contact - Covid-19, Telemedicine, and the Patient-Provider Relationship.
     N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMp2206471.
     PubMed    
     
     
     
208. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Choosing an Antiviral to Treat Covid-19.
     N Engl J Med. 2022;387:e22.
     PubMed    
     
     
     
209. ARBEL R, Wolff Sagy Y, Hoshen M, Battat E, et al
     Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge.
     N Engl J Med. 2022 Aug 24. doi: 10.1056/NEJMoa2204919.
     PubMed     Abstract available
     
     
     
210. ABDOOL KARIM SS, Devnarain N
     Time to Stop Using Ineffective Covid-19 Drugs.
     N Engl J Med. 2022;387:654-655.
     PubMed    
     
     
     
211. BRAMANTE CT, Huling JD, Tignanelli CJ, Buse JB, et al
     Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19.
     N Engl J Med. 2022;387:599-610.
     PubMed     Abstract available
     
     
     
212. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Combating Covid-19 Today and Tomorrow.
     N Engl J Med. 2022;387:e17.
     PubMed    
     
     
     
213. JOST TS
     Considering Race and Ethnicity in Covid Risk Assessments - Legal Concerns and Possible Solutions.
     N Engl J Med. 2022;387:481-483.
     PubMed    
     
     
     
214. KOHANE I, Omenn GS
     Understanding Covid Vaccine Efficacy over Time - Bridging a Gap Between Public Health and Health Care.
     N Engl J Med. 2022 Aug 6. doi: 10.1056/NEJMp2201084.
     PubMed    
     
     
     
215. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Updated Covid-19 Vaccines and a Look at Monkeypox.
     N Engl J Med. 2022;387:e16.
     PubMed    
     
     
     
216. TAKASHITA E, Yamayoshi S, Simon V, van Bakel H, et al
     Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants.
     N Engl J Med. 2022;387:468-470.
     PubMed    
     
     
     July 2022
217. RUBIN EJ, Baden LR, Currier JS, Morrissey S, et al
     Audio Interview: Reinventing the Research Infrastructure to Address Covid-19.
     N Engl J Med. 2022;387:e13.
     PubMed    
     
     
     
218. RUBIN EJ, Baden LR, Jha A, Morrissey S, et al
     Audio Interview: A Look at the U.S. Government's Covid-19 Strategy.
     N Engl J Med. 2022;387:e11.
     PubMed    
     
     
     
219. TAN SHX, Cook AR, Heng D, Ong B, et al
     Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.
     N Engl J Med. 2022 Jul 20. doi: 10.1056/NEJMoa2203209.
     PubMed     Abstract available
     
     
     
220. MAIER HE, Balmaseda A, Saborio S, Ojeda S, et al
     Protection Associated with Previous SARS-CoV-2 Infection in Nicaragua.
     N Engl J Med. 2022 Jul 20. doi: 10.1056/NEJMc2203985.
     PubMed    
     
     
     
221. HAMMOND J, Bao W, Simon-Campos A
     Nirmatrelvir for Nonhospitalized Adults with Covid-19. Reply.
     N Engl J Med. 2022;387.
     PubMed    
     
     
     
222. MORRIS AM, Lee TC
     Nirmatrelvir for Nonhospitalized Adults with Covid-19.
     N Engl J Med. 2022;387.
     PubMed    
     
     
     
223. CHEN BS, Hung CH, Wei JC
     Nirmatrelvir for Nonhospitalized Adults with Covid-19.
     N Engl J Med. 2022;387.
     PubMed    
     
     
     
224. RUBIN EJ, Baden LR, Marks P, Morrissey S, et al
     Audio Interview: Covid-19 Vaccines and the FDA.
     N Engl J Med. 2022;387:e10.
     PubMed    
     
     
     
225. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Designing the Next Covid-19 Vaccine.
     N Engl J Med. 2022;387:e6.
     PubMed    
     
     
     
226. ZHAO X, Zhang R, Qiao S, Wang X, et al
     Omicron SARS-CoV-2 Neutralization from Inactivated and ZF2001 Vaccines.
     N Engl J Med. 2022 Jul 6. doi: 10.1056/NEJMc2206900.
     PubMed    
     
     
     June 2022
227. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: How Effective is Covid-19 Vaccination in Children?
     N Engl J Med. 2022;386:e78.
     PubMed    
     
     
     
228. WAXMAN JG, Magen O, Hernan MA
     Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine. Reply.
     N Engl J Med. 2022;387.
     PubMed    
     
     
     
229. TUMMINIA A, Romano M
     Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine.
     N Engl J Med. 2022;387.
     PubMed    
     
     
     
230. COHEN-STAVI CJ, Magen O, Barda N, Yaron S, et al
     BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age.
     N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMoa2205011.
     PubMed     Abstract available
     
     
     
231. BOUCAU J, Marino C, Regan J, Uddin R, et al
     Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection.
     N Engl J Med. 2022 Jun 29. doi: 10.1056/NEJMc2202092.
     PubMed    
     
     
     
232. SCHONBORN L, Seck SE, Thiele T, Warkentin TE, et al
     SARS-CoV-2 Infection in Patients with a History of VITT.
     N Engl J Med. 2022 Jun 27. doi: 10.1056/NEJMc2206601.
     PubMed    
     
     
     
233. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Vaccinating Young Children against Covid-19.
     N Engl J Med. 2022;386:e77.
     PubMed    
     
     
     
234. BAR-ON YM, Goldberg Y, Milo R
     Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. Reply.
     N Engl J Med. 2022;386:2441-2442.
     PubMed    
     
     
     
235. WOHL A, Leibowitz R
     Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
     N Engl J Med. 2022;386:2441.
     PubMed    
     
     
     
236. DESILVA M, Haapala J, Vazquez-Benitez G, Vesco KK, et al
     Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy.
     N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2205276.
     PubMed    
     
     
     
237. HALASA NB, Olson SM, Staat MA, Newhams MM, et al
     Maternal Vaccination and Risk of Hospitalization for Covid-19 among Infants.
     N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMoa2204399.
     PubMed     Abstract available
     
     
     
238. RASMUSSEN SA, Jamieson DJ
     Covid-19 Vaccination during Pregnancy - Two for the Price of One.
     N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMe2206730.
     PubMed    
     
     
     
239. HACHMANN NP, Miller J, Collier AY, Ventura JD, et al
     Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5.
     N Engl J Med. 2022 Jun 22. doi: 10.1056/NEJMc2206576.
     PubMed    
     
     
     
240. RUBIN EJ, Baden LR, Abraham J, Morrissey S, et al
     Audio Interview: Viral Evolution and the Future of Monoclonal Antibodies.
     N Engl J Med. 2022;386:e75.
     PubMed    
     
     
     
241. PRICE AM, Olson SM, Patel MM
     BNT162b2 Protection against the Omicron Variant in Children and Adolescents. Reply.
     N Engl J Med. 2022;386:2346.
     PubMed    
     
     
     
242. ZENG G
     BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
     N Engl J Med. 2022;386:2345-2346.
     PubMed    
     
     
     
243. LEUCHTER RK, Jackson NJ, Mafi JN, Sarkisian CA, et al
     Association between Covid-19 Vaccination and Influenza Vaccination Rates.
     N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMc2204560.
     PubMed    
     
     
     
244. QU P, Faraone J, Evans JP, Zou X, et al
     Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants.
     N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMc2206725.
     PubMed    
     
     
     
245. HOPKINS S, Hall V, Klenerman P
     Protection against SARS-CoV-2 after Vaccination and Previous Infection. Reply.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
246. MATUCHANSKY C
     Protection against SARS-CoV-2 after Vaccination and Previous Infection.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
247. ALTARAWNEH HN, Chemaitelly H, Ayoub HH, Tang P, et al
     Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
     N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMoa2203965.
     PubMed     Abstract available
     
     
     
248. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Protecting the Immunocompromised from Covid-19.
     N Engl J Med. 2022;386:e71.
     PubMed    
     
     
     
249. ABRAHAM J
     Monoclonal Antibodies with Extended Half-Life to Prevent Covid-19.
     N Engl J Med. 2022;386:2236-2238.
     PubMed    
     
     
     
250. JOLOBE OMP
     Protection Due to Previous SARS-CoV-2 Infection.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
251. SCHERER EM, Babiker A, Adelman MW, Allman B, et al
     SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients.
     N Engl J Med. 2022 Jun 8. doi: 10.1056/NEJMc2202861.
     PubMed    
     
     
     
252. RUBIN EJ, Baden LR, Moore PL, Morrissey S, et al
     Audio Interview: Dissecting the Host Response to SARS-CoV-2.
     N Engl J Med. 2022;386:e69.
     PubMed    
     
     
     May 2022
253. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Waning Immunity against Covid-19.
     N Engl J Med. 2022;386:e64.
     PubMed    
     
     
     
254. ACCORSI EK, Britton A, Shang N, Fleming-Dutra KE, et al
     Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron.
     N Engl J Med. 2022 May 25. doi: 10.1056/NEJMc2203165.
     PubMed    
     
     
     
255. GOLDBERG Y, Mandel M, Bar-On YM, Bodenheimer O, et al
     Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
     N Engl J Med. 2022 May 25. doi: 10.1056/NEJMoa2118946.
     PubMed     Abstract available
     
     
     
256. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: What to Make of Covid-19 Hot Spots.
     N Engl J Med. 2022;386:e63.
     PubMed    
     
     
     
257. BROWN PE, Fu SH, Bansal A, Newcombe L, et al
     Omicron BA.1/1.1 SARS-CoV-2 Infection among Vaccinated Canadian Adults.
     N Engl J Med. 2022 May 18. doi: 10.1056/NEJMc2202879.
     PubMed    
     
     
     
258. EVANS JP, Qu P, Zeng C, Zheng YM, et al
     Neutralization of the SARS-CoV-2 Deltacron and BA.3 Variants.
     N Engl J Med. 2022 May 18. doi: 10.1056/NEJMc2205019.
     PubMed    
     
     
     
259. RUBIN EJ, Baden LR, Lipsitch M, Morrissey S, et al
     Audio Interview: Forecasting the Future of Covid.
     N Engl J Med. 2022;386:e58.
     PubMed    
     
     
     
260. CREECH CB, Anderson E, Berthaud V, Yildirim I, et al
     Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age.
     N Engl J Med. 2022 May 11. doi: 10.1056/NEJMoa2203315.
     PubMed     Abstract available
     
     
     
261. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Do We Need New Covid-19 Vaccines?
     N Engl J Med. 2022;386:e52.
     PubMed    
     
     
     
262. ESTCOURT L, Callum J
     Convalescent Plasma for Covid-19 - Making Sense of the Inconsistencies.
     N Engl J Med. 2022;386:1753-1754.
     PubMed    
     
     
     
263. PERSAD G, Pandya A
     A Comprehensive Covid-19 Response - The Need for Economic Evaluation.
     N Engl J Med. 2022 May 4. doi: 10.1056/NEJMp2202828.
     PubMed    
     
     
     
264. HAGER KJ, Perez Marc G, Gobeil P, Diaz RS, et al
     Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
     N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2201300.
     PubMed     Abstract available
     
     
     
265. DAI L, Gao L, Tao L, Hadinegoro SR, et al
     Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
     N Engl J Med. 2022 May 4. doi: 10.1056/NEJMoa2202261.
     PubMed     Abstract available
     
     
     
266. NOHYNEK H, Wilder-Smith A
     Does the World Still Need New Covid-19 Vaccines?
     N Engl J Med. 2022 May 4. doi: 10.1056/NEJMe2204695.
     PubMed    
     
     
     
267. GRAY G, Collie S, Goga A, Garrett N, et al
     Effectiveness of Ad26.COV2.S and BNT162b2 Vaccines against Omicron Variant in South Africa.
     N Engl J Med. 2022 May 4. doi: 10.1056/NEJMc2202061.
     PubMed    
     
     
     April 2022
268. RUBIN EJ, Baden LR, Marrazzo JM, Morrissey S, et al
     Audio Interview: Communicating Covid-19 Science.
     N Engl J Med. 2022;386:e53.
     PubMed    
     
     
     
269. RUBIN EJ, Baden LR, Inglefinger JR, Morrissey S, et al
     Audio Interview: The Effects of Covid-19 on Children.
     N Engl J Med. 2022;386:e51.
     PubMed    
     
     
     
270. BHATTACHARYYA RP, Hanage WP
     Intrinsic Severity of the SARS-CoV-2 Omicron Variant. Reply.
     N Engl J Med. 2022 Apr 20. pii: 10.1056/NEJMc2203679.
     PubMed    
     
     
     
271. SHAFER SL
     Intrinsic Severity of the SARS-CoV-2 Omicron Variant.
     N Engl J Med. 2022 Apr 20. pii: 10.1056/NEJMc2203679.
     PubMed    
     
     
     
272. LEVIN MJ, Ustianowski A, De Wit S, Launay O, et al
     Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.
     N Engl J Med. 2022 Apr 20. doi: 10.1056/NEJMoa2116620.
     PubMed     Abstract available
     
     
     
273. OFFIT PA
     Covid-19 Boosters - Where from Here?
     N Engl J Med. 2022 Apr 13. doi: 10.1056/NEJMe2203329.
     PubMed    
     
     
     
274. MAGEN O, Waxman JG, Makov-Assif M, Vered R, et al
     Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting.
     N Engl J Med. 2022 Apr 13. doi: 10.1056/NEJMoa2201688.
     PubMed     Abstract available
     
     
     
275. DRAIN PK
     Rapid Diagnostic Testing for SARS-CoV-2. Reply.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
276. BOGATY P
     Rapid Diagnostic Testing for SARS-CoV-2.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
277. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Do We Need a Fourth Dose of Covid Vaccine?
     N Engl J Med. 2022;386:e45.
     PubMed    
     
     
     
278. MOORE PL, Baden LR
     Omicron - Decoupling Infection from Severe Disease.
     N Engl J Med. 2022;386:1361-1362.
     PubMed    
     
     
     
279. HORWITZ JR, Wiley LF
     Not Ready for the End Game - Why Ending Federal Covid-19 Emergency Declarations Will Harm Access to Care.
     N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMp2203468.
     PubMed    
     
     
     
280. YOON SK, Hegmann KT, Thiese MS, Burgess JL, et al
     Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers.
     N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMc2201821.
     PubMed    
     
     
     
281. LEE KC, Morgan AU, Chaiyachati KH, Asch DA, et al
     Pulse Oximetry for Monitoring Patients with Covid-19 at Home - A Pragmatic, Randomized Trial.
     N Engl J Med. 2022 Apr 6. doi: 10.1056/NEJMc2201541.
     PubMed    
     
     
     
282. BAR-ON YM, Goldberg Y, Mandel M, Bodenheimer O, et al
     Protection by a Fourth Dose of BNT162b2 against Omicron in Israel.
     N Engl J Med. 2022 Apr 5. doi: 10.1056/NEJMoa2201570.
     PubMed     Abstract available
     
     
     March 2022
283. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Effectiveness of Covid-19 Vaccination in Children.
     N Engl J Med. 2022;386:e39.
     PubMed    
     
     
     
284. KLEIN NP
     Added Benefit of Covid-19 Vaccination after Previous Infection.
     N Engl J Med. 2022;386:1278-1279.
     PubMed    
     
     
     
285. REIS G, Silva EASM, Silva DCM, Thabane L, et al
     Effect of Early Treatment with Ivermectin among Patients with Covid-19.
     N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2115869.
     PubMed     Abstract available
     
     
     
286. PRICE AM, Olson SM, Newhams MM, Halasa NB, et al
     BNT162b2 Protection against the Omicron Variant in Children and Adolescents.
     N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2202826.
     PubMed     Abstract available
     
     
     
287. SULLIVAN DJ, Gebo KA, Shoham S, Bloch EM, et al
     Early Outpatient Treatment for Covid-19 with Convalescent Plasma.
     N Engl J Med. 2022 Mar 30. doi: 10.1056/NEJMoa2119657.
     PubMed     Abstract available
     
     
     
288. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Covid-19: Why We Publish What We Do.
     N Engl J Med. 2022;386:e38.
     PubMed    
     
     
     
289. VYAS JM, Castle AC, Bourgouin PP, Turbett SE, et al
     Case 9-2022: A 56-Year-Old Woman with Fever, Myalgias, Diarrhea, and Cough.
     N Engl J Med. 2022;386:1166-1174.
     PubMed    
     
     
     
290. ROSSLER A, Knabl L, von Laer D, Kimpel J, et al
     Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection.
     N Engl J Med. 2022 Mar 23. doi: 10.1056/NEJMc2201607.
     PubMed    
     
     
     
291. MOREIRA ED JR, Kitchin N, Xu X, Dychter SS, et al
     Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
     N Engl J Med. 2022 Mar 23. doi: 10.1056/NEJMoa2200674.
     PubMed     Abstract available
     
     
     
292. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Can We Make More Effective Covid-19 Vaccines?
     N Engl J Med. 2022;386:e36.
     PubMed    
     
     
     
293. REGEV-YOCHAY G, Gonen T, Gilboa M, Mandelboim M, et al
     Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.
     N Engl J Med. 2022 Mar 16. doi: 10.1056/NEJMc2202542.
     PubMed    
     
     
     
294. SHAPIRO AE, Gupta A
     Early Treatment with Sotrovimab for Covid-19. Reply.
     N Engl J Med. 2022 Mar 16. pii: 10.1056/NEJMc2201606.
     PubMed    
     
     
     
295. FUJIWARA Y
     Early Treatment with Sotrovimab for Covid-19.
     N Engl J Med. 2022 Mar 16. pii: 10.1056/NEJMc2201606.
     PubMed    
     
     
     
296. ORIGUEN J, Caro-Teller JM, Lopez-Medrano F
     Early Treatment with Sotrovimab for Covid-19.
     N Engl J Med. 2022 Mar 16. pii: 10.1056/NEJMc2201606.
     PubMed    
     
     
     
297. HATZL S, Krause R, Schilcher G
     Early Treatment with Sotrovimab for Covid-19.
     N Engl J Med. 2022 Mar 16. pii: 10.1056/NEJMc2201606.
     PubMed    
     
     
     
298. YU J, Collier AY, Rowe M, Mardas F, et al
     Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.
     N Engl J Med. 2022 Mar 16. doi: 10.1056/NEJMc2201849.
     PubMed    
     
     
     
299. DE ANDA C, Johnson MG, Pedley A
     Molnupiravir for Covid-19 in Nonhospitalized Patients. Reply.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
300. ROBERFROID D, Jespers V, Hulstaert F
     Molnupiravir for Covid-19 in Nonhospitalized Patients.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
301. LEVENSTEIN S
     Molnupiravir for Covid-19 in Nonhospitalized Patients.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
302. SELVI-SABATER P, Abellon-Ruiz J
     Molnupiravir for Covid-19 in Nonhospitalized Patients.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
303. THORLUND K, Sheldrick K, Mills E
     Molnupiravir for Covid-19 in Nonhospitalized Patients.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
304. RUBIN EJ, Baden LR, Hunter D, Morrissey S, et al
     Audio Interview: Making Covid-19 Vaccines Available around the World.
     N Engl J Med. 2022;386:e31.
     PubMed    
     
     
     
305. TAKASHITA E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, et al
     Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2.
     N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMc2201933.
     PubMed    
     
     
     
306. ABU-RADDAD LJ, Chemaitelly H, Ayoub HH, AlMukdad S, et al
     Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
     N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMoa2200797.
     PubMed     Abstract available
     
     
     
307. ROCKETT R, Basile K, Maddocks S, Fong W, et al
     Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use.
     N Engl J Med. 2022 Mar 9. doi: 10.1056/NEJMc2120219.
     PubMed    
     
     
     
308. MONTO AS
     The Future of SARS-CoV-2 Vaccination. Reply.
     N Engl J Med. 2022;386:899-900.
     PubMed    
     
     
     
309. BACHMANN MF, Mohsen MO, Speiser DE
     The Future of SARS-CoV-2 Vaccination.
     N Engl J Med. 2022;386:899.
     PubMed    
     
     
     
310. RUBIN EJ, Baden LR, Morrissey S
     Audio Interview: Using Our Covid-19 Experience to Develop Vaccines More Quickly.
     N Engl J Med. 2022;386:e29.
     PubMed    
     
     
     
311. GEE JE, Bower WA, Kunkel A, Petras J, et al
     Multistate Outbreak of Melioidosis Associated with Imported Aromatherapy Spray.
     N Engl J Med. 2022;386:861-868.
     PubMed     Abstract available
     
     
     
312. MELLO MM, Parmet WE
     U.S. Public Health Law - Foundations and Emerging Shifts.
     N Engl J Med. 2022;386:805-808.
     PubMed    
     
     
     
313. ZHAO X, Li D, Ruan W, Chen Z, et al
     Effects of a Prolonged Booster Interval on Neutralization of Omicron Variant.
     N Engl J Med. 2022;386:894-896.
     PubMed    
     
     
     
314. WALTER EB, Talaat KR, Gurtman A
     More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
315. LEIBOWITZ R, Schurr E, Hirsch O
     More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
316. TAYTARD J, Prevost B, Corvol H
     More on BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
     N Engl J Med. 2022;386.
     PubMed    
     
     
     
317. ANDREWS N, Stowe J, Kirsebom F, Toffa S, et al
     Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.
     N Engl J Med. 2022 Mar 2. doi: 10.1056/NEJMoa2119451.
     PubMed     Abstract available
     
     
     February 2022
318. FLEISHER LA, Schreiber M, Cardo D, Srinivasan A, et al
     Health Care Safety during the Pandemic and Beyond - Building a System That Ensures Resilience.
     N Engl J Med. 2022;386:609-611.
     PubMed    
     
     
     January 2022
319. MEVORACH D, Anis E, Cedar N, Hasin T, et al
     Myocarditis after BNT162b2 Vaccination in Israeli Adolescents.
     N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMc2116999.
     PubMed    
     
     
     
320. PAI M, Kasaeva T, Swaminathan S
     Covid-19's Devastating Effect on Tuberculosis Care - A Path to Recovery.
     N Engl J Med. 2022 Jan 5. doi: 10.1056/NEJMp2118145.
     PubMed    
     
     
     August 2021
321. HALL VG, Ferreira VH, Ku T, Ierullo M, et al
     Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients.
     N Engl J Med. 2021 Aug 11. doi: 10.1056/NEJMc2111462.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO COVID-19 is free of charge.